IDEXX Laboratories Inc., a prominent player in the animal health sector, unveiled its fourth-quarter 2025 financial results and provided guidance for fiscal year 2026. The company reported diluted earnings per share (EPS) of $3.08, marking an 18% increase compared to the previous year and surpassing analyst consensus estimates of $2.94. When adjusted for comparable earnings, the company posted $2.92 per share, underscoring its core profitability performance.
Revenue for the quarter reached $1.091 billion, exceeding market expectations of $1.073 billion. This figure represents a 14% increase on a reported basis and a 12% increase organically, reflecting robust demand and execution across the company’s product and service lines.
Jay Mazelsky, President and CEO, expressed optimism about the company’s trajectory in a Monday press statement, pointing to a dynamic innovation pipeline and growth in installed instrument and software bases globally. “We enter 2026 with an exciting innovation pipeline, expanding instrument and software installed bases, and strong momentum across our global business,” Mazelsky stated, emphasizing strategic positioning ahead of the new fiscal year.
Looking ahead, IDEXX anticipates fiscal year 2026 EPS in the range of $14.29 to $14.80, a projection closely aligned with the prevailing consensus figure of $14.39. The company projects total annual sales between $4.632 billion and $4.720 billion, slightly varying from the consensus forecast of $4.658 billion. This expected growth is largely attributable to recurring revenue within the company’s CAG Diagnostics segment, forecasted to grow between 8.6% and 10.6% reported, and 8.0% to 10.0% organically.
Following the earnings release, IDEXX Laboratories’ shares experienced a positive response in trading. The stock advanced 1.7% to close at $650.54 on the subsequent Tuesday, reflecting investor confidence in the company’s outlined growth prospects and recent financial performance.
Investor analysts adjusted their outlooks on IDEXX following the quarterly results announcement, revising price targets while maintaining their respective ratings. Mark Massaro, an analyst at BTIG, preserved his Buy rating on the stock but lowered the price target from $830 to $800, indicating a more cautious but still favorable stance. Similarly, Andrea Alfonso of UBS retained a Neutral rating on IDEXX, with a reduced price target from $750 to $730, signalling a tempered forecast adjusted for recent developments.
These changes in analyst price targets suggest a market environment where solid near-term results and growth prospects are balanced by underlying uncertainties and potential challenges ahead.
For prospective investors evaluating IDEXX Laboratories, these insights provide a balanced view of the company’s financial health, growth trajectory, and market expectations as reflected in analyst commentary following robust quarterly performance.